

SEQUENCE LISTING

<110> Xie, Xiaoling
Gu, Yong
Markland, William
Su, Michael S.
Caron, Paul R.
Fox, Edward
Wilson, Keith P.
Vertex Pharmaceuticals, Inc.

<120> CRYSTALLIZABLE JNK COMPLEXES

<130> VPI/98-04 CON

<140>

<141>

<150> PCT/US99/09824, 60/084,056

<151> 1999-05-04, 1998-05-04

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 422

<212> PRT

<213> Homo sapiens

<220>

<223> JNK3

<400> 1

Met	Ser	Leu	His	Phe	Leu	Tyr	Tyr	Cys	Ser	Glu	Pro	Thr	Leu	Asp	Val
1				5					10					15	
Lys	Ile	Ala	Phe	Cys	Gln	Gly	Phe	Asp	Lys	Gln	Val	Asp	Val	Ser	Tyr
		20						25					30		
Ile	Ala	Lys	His	Tyr	Asn	Met	Ser	Lys	Ser	Lys	Val	Asp	Asn	Gln	Phe
		35					40					45			
Tyr	Ser	Val	Glu	Val	Gly	Asp	Ser	Thr	Phe	Thr	Val	Leu	Lys	Arg	Tyr
	50					55					60				
Gln	Asn	Leu	Lys	Pro	Ile	Gly	Ser	Gly	Ala	Gln	Gly	Ile	Val	Cys	Ala
65					70					75				80	
Ala	Tyr	Asp	Ala	Val	Leu	Asp	Arg	Asn	Val	Ala	Ile	Lys	Lys	Leu	Ser
			85						90					95	
Arg	Pro	Phe	Gln	Asn	Gln	Thr	His	Ala	Lys	Arg	Ala	Tyr	Arg	Glu	Leu
			100					105					110		
Val	Leu	Met	Lys	Cys	Val	Asn	His	Lys	Asn	Ile	Ile	Ser	Leu	Leu	Asn
		115					120					125			
Val	Phe	Thr	Pro	Gln	Lys	Thr	Leu	Glu	Glu	Phe	Gln	Asp	Val	Tyr	Leu
	130					135					140				
Val	Met	Glu	Leu	Met	Asp	Ala	Asn	Leu	Cys	Gln	Val	Ile	Gln	Met	Glu

145 150 155 160
 Leu Asp His Glu Arg Met Ser Tyr Leu Leu Tyr Gln Met Leu Cys Gly
 165 170 175
 Ile Lys His Leu His Ser Ala Gly Ile Ile His Arg Asp Leu Lys Pro
 180 185 190
 Ser Asn Ile Val Val Lys Ser Asp Cys Thr Leu Lys Ile Leu Asp Phe
 195 200 205
 Gly Leu Ala Arg Thr Ala Gly Thr Ser Phe Met Met Thr Pro Tyr Val
 210 215 220
 Val Thr Arg Tyr Tyr Arg Ala Pro Glu Val Ile Leu Gly Met Gly Tyr
 225 230 235 240
 Lys Glu Asn Val Asp Ile Trp Ser Val Gly Cys Ile Met Gly Glu Met
 245 250 255
 Val Arg His Lys Ile Leu Phe Pro Gly Arg Asp Tyr Ile Asp Gln Trp
 260 265 270
 Asn Lys Val Ile Glu Gln Leu Gly Thr Pro Cys Pro Glu Phe Met Lys
 275 280 285
 Lys Leu Gln Pro Thr Val Arg Asn Tyr Val Glu Asn Arg Pro Lys Tyr
 290 295 300
 Ala Gly Leu Thr Phe Pro Lys Leu Phe Pro Asp Ser Leu Phe Pro Ala
 305 310 315 320
 Asp Ser Glu His Asn Lys Leu Lys Ala Ser Gln Ala Arg Asp Leu Leu
 325 330 335
 Ser Lys Met Leu Val Ile Asp Pro Ala Lys Arg Ile Ser Val Asp Asp
 340 345 350
 Ala Leu Gln His Pro Tyr Ile Asn Val Trp Tyr Asp Pro Ala Glu Val
 355 360 365
 Glu Ala Pro Pro Pro Gln Ile Tyr Asp Lys Gln Leu Asp Glu Arg Glu
 370 375 380
 His Thr Ile Glu Glu Trp Lys Glu Leu Ile Tyr Lys Glu Val Met Asn
 385 390 395 400
 Ser Glu Glu Lys Thr Lys Asn Gly Val Val Lys Gly Gln Pro Ser Pro
 405 410 415
 Ser Ala Gln Val Gln Gln
 420

<210> 2
 <211> 39
 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Description of Artificial Sequence: primer

<400> 2
gctctagagc tccatgggca gcaaaagcaa agttgacaa

39

<210> 3
<211> 37
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 3
tagcggatcc tcattctgaa ttcattactt ccttgta

37

<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: glycine-rich
phosphate anchor loop

<220>

<223> Xaa throughout the sequence may be any amino acid

<400> 4
Gly Xaa Gly Xaa Gly Xaa Xaa
1 5

<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: glycine-rich
peptide

<400> 5
Gly Ser Gly Ala Gln Gly Ile Val
1 5

<210> 6
<211> 21
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EGF receptor
peptide

<400> 6
Lys Arg Glu Leu Val Glu Pro Leu Thr Pro Ser Gly Glu Ala Pro Asn
1 5 10 15

Gln Ala Leu Leu Arg
20